Table 2.
Participant demographics at initiation of insulin degludec therapy
| Variables | 0–120 min group (n = 12)a | 121–240 min group (n = 11)a | p value |
|---|---|---|---|
| Age (years) | 68.9 ± 8.7 | 65.2 ± 13.1 | 0.426 |
| Female | 33.3% | 36.4% | 0.611 |
| Body weight (kg) | 64.1 ± 12.0 | 69.5 ± 21.2 | 0.472 |
| Body mass index (kg/m2) | 24.6 ± 2.2 | 25.5 ± 5.0 | 0.630 |
| HbA1c (%) | 8.17 ± 1.17 | 7.96 ± 1.24 | 0.691 |
| Fasting plasma glucose (mg/dl) | 144.6 ± 42.3 | 146.6 ± 41.6 | 0.916 |
| Frequency of IGla (times/day) | 1.4 ± 0.5 | 1.4 ± 0.5 | 0.159 |
| Frequency of hypoglycemia (episodes/month) | 0.2 ± 0.4 | 3.8 ± 7.9 | 0.806 |
| Difference in dose timing of IGla (min) | 60.1 ± 38.0 | 203.6 ± 34.1 | <0.001*** |
| Dose of IGla (units/day) | 21.4 ± 11.4 | 17.9 ± 8.6 | 0.418 |
| Basal bolus therapy | 50.0% | 54.5% | 0.827 |
*** p < 0.001
Values in table are presented as the mean ± SD or as a percentage
a0–120 min, patients whose difference in dose timing of long-acting insulin was between 0 and 120 min. 120–240 min, patients whose difference in dose timing of long-acting insulin was between 121 and 240 min